Dina Ramadane
Stock Analyst at Bank of America Securities
(2.59)
# 2,983
Out of 5,144 analysts
36
Total ratings
38.1%
Success rate
4.9%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Dina Ramadane
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| PROK ProKidney | Reiterated: Sell | n/a | $1.10 | - | 6 | Nov 13, 2026 | |
| IMVT Immunovant | Reiterated: Buy | $45 → $46 | $33.21 | +38.51% | 4 | Nov 9, 2026 | |
| VERA Vera Therapeutics | Reiterated: Buy | n/a | $26.20 | - | 14 | Nov 6, 2026 | |
| BHVN Biohaven | Reiterated: Sell | n/a | $13.24 | - | 11 | Oct 30, 2026 | |
| AMLX Amylyx Pharmaceuticals | Reiterated: Buy | $22 | $27.52 | -20.06% | 1 | May 7, 2026 |
ProKidney
Nov 13, 2026
Reiterated: Sell
Price Target: n/a
Current: $1.10
Upside: -
Immunovant
Nov 9, 2026
Reiterated: Buy
Price Target: $45 → $46
Current: $33.21
Upside: +38.51%
Vera Therapeutics
Nov 6, 2026
Reiterated: Buy
Price Target: n/a
Current: $26.20
Upside: -
Biohaven
Oct 30, 2026
Reiterated: Sell
Price Target: n/a
Current: $13.24
Upside: -
Amylyx Pharmaceuticals
May 7, 2026
Reiterated: Buy
Price Target: $22
Current: $27.52
Upside: -20.06%